CIPLA VALGANCICLOVIR valganciclovir (as hydrochloride) 450 mg tablet bottle

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

valganciclovir hydrochloride, Quantity: 496.3 mg (Equivalent: valganciclovir, Qty 450 mg)

Disponibbli minn:

Cipla Australia Pty Ltd

INN (Isem Internazzjonali):

Valganciclovir hydrochloride

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: povidone; stearic acid; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000; iron oxide red

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

60 tablets

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

CIPLA VALGANCICLOVIR is indicated for the treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).,CIPLA VALGANCICLOVIR is indicated for the prophylaxis of CMV disease in adult and paediatric solid organ transplantation (SOT) patients who are at risk.

Sommarju tal-prodott:

Visual Identification: Pink coloured, capsule shaped, biconvex film coated tablet plain on both sides; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2016-09-02